293 related articles for article (PubMed ID: 22889147)
41. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
[TBL] [Abstract][Full Text] [Related]
42. Trial will evaluate a once-daily dose of raltegravir.
AIDS Patient Care STDS; 2008 Nov; 22(11):918-9. PubMed ID: 19043842
[No Abstract] [Full Text] [Related]
43. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
Cabrera C
Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
[TBL] [Abstract][Full Text] [Related]
44. FDA approves raltegravir tablets.
AIDS Patient Care STDS; 2007 Nov; 21(11):889. PubMed ID: 18240897
[No Abstract] [Full Text] [Related]
45. [Raltegravir as first integrase inhibitor in an HIV-infection].
Papendorp SG; Brinkman K
Ned Tijdschr Geneeskd; 2009 Jan; 153(5):166-7. PubMed ID: 19256240
[No Abstract] [Full Text] [Related]
46. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
[No Abstract] [Full Text] [Related]
47. Five years' real-life experience with raltegravir in a large HIV centre.
van Halsema C; Whitfield T; Lin N; Ashton K; Torkington A; Ustianowski A
Int J STD AIDS; 2016 Apr; 27(5):387-93. PubMed ID: 25931236
[TBL] [Abstract][Full Text] [Related]
48. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
[TBL] [Abstract][Full Text] [Related]
49. Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy.
Besson GJ; McMahon D; Maldarelli F; Mellors JW
Clin Infect Dis; 2012 Feb; 54(3):451-3. PubMed ID: 22016501
[No Abstract] [Full Text] [Related]
50. Raltegravir: the first HIV type 1 integrase inhibitor.
Hicks C; Gulick RM
Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
[TBL] [Abstract][Full Text] [Related]
51. Raltegravir and etravirine are active against HIV type 1 group O.
Briz V; Garrido C; Poveda E; Morello J; Barreiro P; de Mendoza C; Soriano V
AIDS Res Hum Retroviruses; 2009 Feb; 25(2):225-7. PubMed ID: 19239363
[TBL] [Abstract][Full Text] [Related]
52. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
Gatell JM; Katlama C; Grinsztejn B; Eron JJ; Lazzarin A; Vittecoq D; Gonzalez CJ; Danovich RM; Wan H; Zhao J; Meibohm AR; Strohmaier KM; Harvey CM; Isaacs RD; Nguyen BY;
J Acquir Immune Defic Syndr; 2010 Apr; 53(4):456-63. PubMed ID: 20306554
[TBL] [Abstract][Full Text] [Related]
53. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
McMahon D; Jones J; Wiegand A; Gange SJ; Kearney M; Palmer S; McNulty S; Metcalf JA; Acosta E; Rehm C; Coffin JM; Mellors JW; Maldarelli F
Clin Infect Dis; 2010 Mar; 50(6):912-9. PubMed ID: 20156060
[TBL] [Abstract][Full Text] [Related]
54. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
Evering TH; Markowitz M
Drugs Today (Barc); 2007 Dec; 43(12):865-77. PubMed ID: 18174972
[TBL] [Abstract][Full Text] [Related]
55. Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.
Stephan C; Baldauf HM; Barry J; Giordano FA; Bartholomae CC; Haberl A; Bickel M; Schmidt M; Laufs S; Kaderali L; Keppler OT
J Antimicrob Chemother; 2014 Oct; 69(10):2809-18. PubMed ID: 24962031
[TBL] [Abstract][Full Text] [Related]
56. Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.
Perry CM
Paediatr Drugs; 2014 Feb; 16(1):91-100. PubMed ID: 24277175
[TBL] [Abstract][Full Text] [Related]
57. Treatment of HIV infection with raltegravir.
Chirch LM; Morrison S; Steigbigel RT
Expert Opin Pharmacother; 2009 May; 10(7):1203-11. PubMed ID: 19385721
[TBL] [Abstract][Full Text] [Related]
58. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.
Squires KE; Bekker LG; Eron JJ; Cheng B; Rockstroh JK; Marquez F; Kumar P; Thompson M; Campo RE; Mounzer K; Strohmaier KM; Lu C; Rodgers A; Jackson BE; Wenning LA; Robertson M; Nguyen BY; Sklar P;
AIDS Res Hum Retroviruses; 2013 Jun; 29(6):859-70. PubMed ID: 23351187
[TBL] [Abstract][Full Text] [Related]
59. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
Eron JJ; Rockstroh JK; Reynes J; Andrade-Villanueva J; Ramalho-Madruga JV; Bekker LG; Young B; Katlama C; Gatell-Artigas JM; Arribas JR; Nelson M; Campbell H; Zhao J; Rodgers AJ; Rizk ML; Wenning L; Miller MD; Hazuda D; DiNubile MJ; Leavitt R; Isaacs R; Robertson MN; Sklar P; Nguyen BY;
Lancet Infect Dis; 2011 Dec; 11(12):907-15. PubMed ID: 21933752
[TBL] [Abstract][Full Text] [Related]
60. HIV integrase as a target for antiretroviral therapy.
Hazuda DJ
Curr Opin HIV AIDS; 2012 Sep; 7(5):383-9. PubMed ID: 22871634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
